181 related articles for article (PubMed ID: 29608774)
1. B-cell activity markers are associated with different disease activity domains in primary Sjögren's syndrome.
James K; Chipeta C; Parker A; Harding S; Cockell SJ; Gillespie CS; Hallinan J; Barone F; Bowman SJ; Ng WF; Fisher BA;
Rheumatology (Oxford); 2018 Jul; 57(7):1222-1227. PubMed ID: 29608774
[TBL] [Abstract][Full Text] [Related]
2. Comparison of ESSDAI and ClinESSDAI in potential optimisation of trial outcomes in primary Sjögren's syndrome: examination of data from the UK Primary Sjögren's Syndrome Registry.
Dumusc A; Ng WF; James K; Griffiths B; Price E; Pease C; Emery P; Lanyon P; Jones A; Bombardieri M; Sutcliffe N; Pitzalis C; Gupta M; McLaren J; Cooper A; Giles I; Isenberg D; Saravanan V; Coady D; Dasgupta B; McHugh N; Young-Min S; Moots R; Gendi N; Akil M; Barone F; Fisher B; Rauz S; Richards A; Bowman S
Swiss Med Wkly; 2018; 148():w14588. PubMed ID: 29442344
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjögren's syndrome. Data at enrollment in the prospective ASSESS cohort.
Gottenberg JE; Seror R; Miceli-Richard C; Benessiano J; Devauchelle-Pensec V; Dieude P; Dubost JJ; Fauchais AL; Goeb V; Hachulla E; Hatron PY; Larroche C; Le Guern V; Morel J; Perdriger A; Puéchal X; Rist S; Saraux A; Sene D; Sibilia J; Vittecoq O; Nocturne G; Ravaud P; Mariette X
PLoS One; 2013; 8(5):e59868. PubMed ID: 23717383
[TBL] [Abstract][Full Text] [Related]
4. The efficacy and mechanism for action of iguratimod in primary Sjögren's syndrome patients.
Jiang W; Zhang L; Zhao Y; He X; Hu C; Liu Y
Int Ophthalmol; 2020 Nov; 40(11):3059-3065. PubMed ID: 32607949
[TBL] [Abstract][Full Text] [Related]
5. Development and performance of the Clinical Trials ESSDAI (ClinTrialsESSDAI), consisting of frequently active clinical domains, in two randomised controlled trials in primary Sjögren's syndrome.
de Wolff L; Arends S; Pontarini E; Bombardieri M; Bowman SJ; Bootsma H
Clin Exp Rheumatol; 2021; 39 Suppl 133(6):100-106. PubMed ID: 34796851
[TBL] [Abstract][Full Text] [Related]
6. Serum immunoglobulin free light chains are sensitive biomarkers for monitoring disease activity and treatment response in primary Sjögren's syndrome.
Verstappen GM; Moerman RV; van Nimwegen JF; van Ginkel MS; Bijzet J; Mossel E; Vissink A; Hazenberg BPC; Arends S; Kroese FGM; Bootsma H
Rheumatology (Oxford); 2018 Oct; 57(10):1812-1821. PubMed ID: 29982712
[TBL] [Abstract][Full Text] [Related]
7. Elevated expression of BAFF receptor, BR3, on monocytes correlates with B cell activation and clinical features of patients with primary Sjögren's syndrome.
Yoshimoto K; Suzuki K; Takei E; Ikeda Y; Takeuchi T
Arthritis Res Ther; 2020 Jun; 22(1):157. PubMed ID: 32576236
[TBL] [Abstract][Full Text] [Related]
8. Serum 25-Hydroxyvitamin D3 and BAFF Levels Are Associated with Disease Activity in Primary Sjogren's Syndrome.
Lee SJ; Oh HJ; Choi BY; Jang YJ; Lee JY; Park JK; Song YW
J Immunol Res; 2016; 2016():5781070. PubMed ID: 28074193
[TBL] [Abstract][Full Text] [Related]
9. Disease activity and damage in patients with primary Sjogren's syndrome: Prognostic value of salivary gland ultrasonography.
Milic V; Colic J; Cirkovic A; Stanojlovic S; Damjanov N
PLoS One; 2019; 14(12):e0226498. PubMed ID: 31891590
[TBL] [Abstract][Full Text] [Related]
10. Go Ask Your Patients! PSS-QoL Reported Perception of Dryness Correlates With Lacrimal and Salivary Flow in Primary Sjögren's Syndrome.
Lackner A; Bosch P; Zenz S; Horwath-Winter J; Rabensteiner DF; Hermann J; Graninger W; Stradner MH
Front Med (Lausanne); 2021; 8():660580. PubMed ID: 33937295
[No Abstract] [Full Text] [Related]
11. Development of the ClinESSDAI: a clinical score without biological domain. A tool for biological studies.
Seror R; Meiners P; Baron G; Bootsma H; Bowman SJ; Vitali C; Gottenberg JE; Theander E; Tzioufas A; De Vita S; Ramos-Casals M; Dörner T; Quartuccio L; Ravaud P; Mariette X;
Ann Rheum Dis; 2016 Nov; 75(11):1945-1950. PubMed ID: 27150113
[TBL] [Abstract][Full Text] [Related]
12. Baseline disease activity influences subsequent achievement of patient acceptable symptom state in Sjögren's syndrome.
Park EH; Ha YJ; Kang EH; Song YW; Scofield RH; Lee YJ
Rheumatology (Oxford); 2021 Jun; 60(6):2714-2724. PubMed ID: 33188390
[TBL] [Abstract][Full Text] [Related]
13. Identification of definitive serum biomarkers associated with disease activity in primary Sjögren's syndrome.
Nishikawa A; Suzuki K; Kassai Y; Gotou Y; Takiguchi M; Miyazaki T; Yoshimoto K; Yasuoka H; Yamaoka K; Morita R; Yoshimura A; Takeuchi T
Arthritis Res Ther; 2016 May; 18(1):106. PubMed ID: 27180164
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of systemic activity of pediatric primary Sjögren's syndrome by EULAR Sjögren's syndrome disease activity index (ESSDAI).
Kobayashi I; Okura Y; Ueki M; Tozawa Y; Takezaki S; Yamada M; Ariga T
Mod Rheumatol; 2019 Jan; 29(1):130-133. PubMed ID: 29529894
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic accuracy of salivary and serum-free light chain assays in primary Sjögren's syndrome: a pilot study.
Sandhya P; Christudoss P; Kabeerdoss J; Mandal SK; Aithala R; Mahasampath G; Job V; Danda D
Int J Rheum Dis; 2017 Jun; 20(6):760-766. PubMed ID: 28036132
[TBL] [Abstract][Full Text] [Related]
16. Serological lymphocytic activity and patient-reported outcomes in Sjögren's syndrome.
Jülich M; Kanne AM; Sehnert B; Budweiser S; Voll RE; Kollert F
Clin Rheumatol; 2018 Sep; 37(9):2361-2366. PubMed ID: 29858711
[TBL] [Abstract][Full Text] [Related]
17. Epidemiological profile and north-south gradient driving baseline systemic involvement of primary Sjögren's syndrome.
Brito-Zerón P; Acar-Denizli N; Ng WF; Horváth IF; Rasmussen A; Seror R; Li X; Baldini C; Gottenberg JE; Danda D; Quartuccio L; Priori R; Hernandez-Molina G; Armagan B; Kruize AA; Kwok SK; Kvarnstrom M; Praprotnik S; Sene D; Gerli R; Solans R; Rischmueller M; Mandl T; Suzuki Y; Isenberg D; Valim V; Wiland P; Nordmark G; Fraile G; Bootsma H; Nakamura H; Giacomelli R; Devauchelle-Pensec V; Hofauer B; Bombardieri M; Trevisani VFM; Hammenfors D; Pasoto SG; Retamozo S; Gheita TA; Atzeni F; Morel J; Vollenweider C; Zeher M; Sivils K; Xu B; Bombardieri S; Sandhya P; De Vita S; Minniti A; Sánchez-Guerrero J; Kilic L; van der Heijden E; Park SH; Wahren-Herlenius M; Mariette X; Ramos-Casals M;
Rheumatology (Oxford); 2020 Sep; 59(9):2350-2359. PubMed ID: 31873754
[TBL] [Abstract][Full Text] [Related]
18. Severe intestinal dysbiosis is prevalent in primary Sjögren's syndrome and is associated with systemic disease activity.
Mandl T; Marsal J; Olsson P; Ohlsson B; Andréasson K
Arthritis Res Ther; 2017 Oct; 19(1):237. PubMed ID: 29065905
[TBL] [Abstract][Full Text] [Related]
19. EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI) and Other Patient-Reported Outcomes in the Assessment of Glandular Dysfunction in Primary Sjögren's Syndrome.
Ture HY; Kim NR; Nam EJ
Life (Basel); 2023 Sep; 13(10):. PubMed ID: 37895373
[TBL] [Abstract][Full Text] [Related]
20. Systemic involvement in primary Sjogren's syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry).
Ramos-Casals M; Brito-Zerón P; Solans R; Camps MT; Casanovas A; Sopeña B; Díaz-López B; Rascón FJ; Qanneta R; Fraile G; Pérez-Alvarez R; Callejas JL; Ripoll M; Pinilla B; Akasbi M; Fonseca E; Canora J; Nadal ME; de la Red G; Fernández-Regal I; Jiménez-Heredia I; Bosch JA; Ayala MD; Morera-Morales L; Maure B; Mera A; Ramentol M; Retamozo S; Kostov B; ;
Rheumatology (Oxford); 2014 Feb; 53(2):321-31. PubMed ID: 24162151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
